Combination antiretroviral therapy in HIV infection. An economic perspective

PharmacoEconomics

Volumn 10, Issue 2, 1996, Pages 109-113

  Moore, R D ^a   Bartlett, J G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHARMACOECONOMICS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0029785605     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610020-00002     Document Type: Short Survey

References (26)

1. 1. MA Fischl DD Richman MH Grieco 1987 The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex N Engl J Med 317 185 191 3299089 10.1056/NEJM198707233170401 1:STN:280:DyaL2s3lvVSrsg%3D%3D Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185–191
2. 2. JO Kahn SW Lagakos DD Richman 1992 A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection N Engl J Med 327 581 587 1353607 10.1056/NEJM199208273270901 1:STN:280:DyaK38zltVWqsA%3D%3D Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581–587
3. 3. MA Fischl RM Olson SE Follansbee 1993 Zalcitabine compared with zidovudine in patients with advanced HIV-2 infection who received previous zidovudine therapy Ann Intern Med 118 762 768 8097082 1:STN:280:DyaK3s3ivValug%3D%3D Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-2 infection who received previous zidovudine therapy. Ann Intern Med 1993; 118: 762–768
4. 4. HW Murray KE Squires W Weiss 1995 Stavudine in patients with AIDS and AIDS-related complex: ACTG 089 J Infect Dis 171 2 S123 S130 7861017 10.1093/infdis/171.Supplement_2.S123 Murray HW, Squires KE, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: ACTG 089. J Infect Dis 1995; 171 Suppl. 2: S123–S130
5. 5. PA Volberding SW Lagakos MA Koch 1990 Zidovudine in asymptomatic human immunodeficiency virus N Engl J Med 322 941 949 1969115 10.1056/NEJM199004053221401 1:STN:280:DyaK3c7ptVOqtQ%3D%3D Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus. N Engl J Med 1990; 322: 941–949
6. 6. RD Moore JC Keruly RE Chaisson 1996 Duration of the survival benefit of zidovudine therapy in HIV infection Arch Intern Med 156 1073 1077 8638994 10.1001/archinte.1996.00040041073005 1:CAS:528:DyaK28Xkt1aqsr8%3D Moore RD, Keruly JC, Chaisson RE. Duration of the survival benefit of zidovudine therapy in HIV infection. Arch Intern Med 1996; 156: 1073–1077
7. 7. RT D’Aquila VA Johnson SL Welles 1995 Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy Ann Intern Med 122 401 408 7856987 D’Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401–408
8. 8. S Hammer M Katzenstein H Hughes 1995 Nucleoside monotherapy versus combination therapy in HIV-infected adults: a randomized, double-blind placebo-controlled trial in persons with CD4 cell counts 200–500/mm 3 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco (CA) American Society for Microbiology Washington DC [abstract no. LB-1] Hammer S, Katzenstein M, Hughes H, et al. Nucleoside monotherapy versus combination therapy in HIV-infected adults: a randomized, double-blind placebo-controlled trial in persons with CD4 cell counts 200–500/mm 3 [abstract no. LB-1]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20: San Francisco (CA). Washington DC: American Society for Microbiology, 1995
9. 9. JJ Eron SL Benoit J Jemsek 1995 Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter N Engl J Med 333 1662 1669 7477218 10.1056/NEJM199512213332502 1:CAS:528:DyaK28XkvFyqtA%3D%3D Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995; 333: 1662–1669
10. 10. T Ridhy J Leis 1995 Development of drug resistance to HIV-1 protease inhibitors J Biol Chem 270 29621 29623 10.1074/jbc.270.50.29621 Ridhy T, Leis J. Development of drug resistance to HIV-1 protease inhibitors. J Biol Chem 1995; 270: 29621–29623
11. 11. CA Collier RW Coombs DA Schoenfeld 1996 Treatment of human immunodeficiency virus disease N Engl J Med 334 1011 1017 8598838 10.1056/NEJM199604183341602 1:CAS:528:DyaK28XivFait74%3D Collier CA, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus disease. N Engl J Med 1996; 334: 1011–1017
12. 12. R Gulick J Mellors D Havlir 1996 Potent and sustained anti-retroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) 3rd Conference on Retroviruses and Opportunistic Infections Washington DC 1996 Jan 28–Feb 1 Infectious Disease Society of America Alexandria (VA) [abstract no. LB7] Gulick R, Mellors J, Havlir D, et al. Potent and sustained anti-retroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) [abstract no. LB7]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1: Washington DC. Alexandria (VA): Infectious Disease Society of America, 1996
13. 13. F Massari M Conant J Mellors 1996 A phase II open-label randomized study of the triple combination of indinavir, zidovudine and didanosine versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients 3rd Conference on Retroviruses and Opportunistic Infections Washington DC 1996 Jan 28–Feb 1 Infectious Disease Society of America Alexandria (VA) [abstract no. 200] Massari F, Conant M, Mellors J, et al. A phase II open-label randomized study of the triple combination of indinavir, zidovudine and didanosine versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients [abstract no. 200]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1: Washington DC. Alexandria (VA): Infectious Disease Society of America, 1996
14. 14. New drugs for HIV infection. Medical Letter 1996; 38: 35-8
15. 15. IS Fortgang RD Moore 1995 Hospital admissions of HIV-infected patients from 1988 to 1992 in Maryland J Acquir Immune Defic Syndr 8 365 372 1:STN:280:DyaK2M7osl2iug%3D%3D Fortgang IS, Moore RD. Hospital admissions of HIV-infected patients from 1988 to 1992 in Maryland. J Acquir Immune Defic Syndr 1995; 8: 365–372
16. 16. RD Moore J Hidalgo JC Bareta 1994 Zidovudine therapy and health resource utilization in AIDS J Acquir Immune Defic Syndr 7 349 354 8133446 1:STN:280:DyaK2c7otVejug%3D%3D Moore RD. Hidalgo J, Bareta JC, et al. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 1994; 7: 349–354
17. 17. FJ Hellinger 1993 The lifetime cost of treating a person with HIV JAMA 270 474 478 8320787 10.1001/jama.1993.03510040078033 1:STN:280:DyaK3szgvVyjsA%3D%3D Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993; 270: 474–478
18. 18. RE Chaisson JC Keruly RD Moore 1995 Race, sex, drug use, and progression of human immunodeficiency virus disease N Engl J Med 333 751 756 7643881 10.1056/NEJM199509213331202 1:STN:280:DyaK2MzntFOisQ%3D%3D Chaisson RE. Keruly JC. Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995; 333: 751–756
19. 19. WA O’Brien PM Hartigan D Martin 1996 Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS N Engl J Med 334 426 431 8552144 10.1056/NEJM199602153340703 O’Brien WA. Hartigan PM. Martin D. et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426–431
20. 20. SD Paul KM Kuntz KA Eagle 1994 Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure Arch Intern Med 154 1143 1149 8185426 10.1001/archinte.1994.00420100129016 1:STN:280:DyaK2c3ktFyhtw%3D%3D Paul SD, Kuntz KM. Eagle KA. et al. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994; 154: 1143–1149
21. 21. VH Hamilton FE Racicot H Zowall 1995 The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease JAMA 273 1032 1038 7897787 10.1001/jama.1995.03520370074040 1:STN:280:DyaK2M3gsFGntg%3D%3D Hamilton VH. Racicot FE. Zowall H. et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. JAMA 1995; 273: 1032–1038
22. 22. KK Lindfors J Rosenquist 1995 The cost-effectiveness of mammographic screening strategies JAMA 274 881 884 7674501 10.1001/jama.1995.03530110043033 1:STN:280:DyaK2MvgsVyhsg%3D%3D Lindfors KK. Rosenquist J. The cost-effectiveness of mammographic screening strategies. JAMA 1995; 274: 881–884
23. 23. D J Van JH Bond MV Sivak 1995 Fecal occult blood screening for colorectal cancer Arch Int Med 155 2389 2402 10.1001/archinte.1995.00430220037005 Van Dam J, Bond JH. Sivak MV. Fecal occult blood screening for colorectal cancer. Arch Int Med 1995; 155: 2389–2402
24. 24. JC Hornberger 1993 The hemodialysis prescription and cost-effectiveness J Am Soc Nephrol 4 1021 1027 8286709 1:STN:280:DyaK2c7hsVyrsA%3D%3D Hornberger JC. The hemodialysis prescription and cost-effectiveness. J Am Soc Nephrol 1993: 4: 1021–1027
25. 25. BF Gage AB Cardinalli GW Albers 1995 Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation JAMA 274 1839 1845 7500532 10.1001/jama.1995.03530230025025 1:CAS:528:DyaK28XksFWisg%3D%3D Gage BF. Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: 1839–1845
26. 26. MD Krahn JE Mahoney MH Eckman 1994 Screening for prostate cancer JAMA 272 773 780 7521400 10.1001/jama.1994.03520100035030 1:STN:280:DyaK2czlvV2mug%3D%3D Krahn MD, Mahoney JE. Eckman MH. et al. Screening for prostate cancer. JAMA 1994; 272: 773–780